[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607323":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":58,"collaborators":18,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":18,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":18,"enrollmentInfo":68,"targetDuration":18,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":18,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Lahey Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"De-Intensified Arm","EXPERIMENTAL","Less-frequent cystoscopy surveillance",[13],"Diagnostic Test: UroAmp Test (Convergent Genomics, Inc.)",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Surveillance Arm","NO_INTERVENTION","Regular follow-ups and standard care",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DIAGNOSTIC_TEST","UroAmp Test (Convergent Genomics, Inc.)","Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.",[9],[26],{"name":27,"affiliation":28,"role":29},"Matthew B Clements, MD, MS","Lahey Hospital & Medical Center","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Linda Topjian","CONTACT","7817448420","Linda.M.Topjian@lahey.org",{"name":37,"role":33,"phone":18,"phoneExt":18,"email":38},"Colette Osborne","Colette.A.Osborne@lahey.org",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Lahey Hospital and Medical Center","RECRUITING","Burlington","Massachusetts","01805","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-71.19561,42.50482,{"lat":52,"lon":51},[55],{"name":32,"role":33,"phone":56,"phoneExt":18,"email":57},"7817448711","linda.m.topjian@lahey.org",{"type":59,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100607323","using-urine-tumor-dna-to-de-intensify-surveillance-in-non-muscle-invasive-bladder-cancer-100607323",false,"NCT07187063","Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer","Inclusion Criteria:\n\n* AUA high-risk bladder cancer1\n* Received induction BCG or gemcitabine\u002Fdocetaxel\n* Negative initial post-induction therapy assessment (negative cytology and cystoscopy +\u002F- biopsy)\n\nExclusion Criteria:\n\n* High-risk NMIBC within 3 years\n* Prior induction intravesical therapy\n* Variant histology\n* Concurrent upper tract disease","ALL","18 Years",{"count":69,"type":70},56,"ESTIMATED","INTERVENTIONAL",[73],"NA","The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.",[76],"Non-muscle Invasive Bladder Cancer (NMIBC)","2025-09-18",{"date":79,"type":80},"2025-09-22","ACTUAL",{"date":82,"type":80},"2025-01-01",{"date":84,"type":70},"2029-01-01",{"name":5,"class":6},1]